Watching
ADPT · Adaptive Biotechnologies Corporation
Updated ·
Against its published line
Above its line on the last close.
How to read this
The red mark is the published kill line — the price that would prove the thesis wrong. The dot is where the name closed on 9 October 2026; a dot left of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row reads well clear, with a hollow dot to show the figure is off the drawn scale. Rows run tightest first.
Kill line
A weekly close below $25, which would put the shares under the 50-day moving average that MarketBeat put at $25.78 on 5 October 2026. A cut to the $268–278 million FY2026 MRD revenue guidance at the Q3 report would break the business case.
Open pick Medium conviction, opened at $27.37. Since then −3.2% against the S&P 500's +1.9% (−5.1 pp). Kill line at open: $25.00 (weekly close); graded by at the latest.
Catalyst (in 23 days)
How picks are graded →The thesis
Adaptive Biotechnologies' clonoSEQ blood-cancer test gained two multiple myeloma endorsements in September 2026, and the case for higher test volume stands even as the shares keep giving back the rally. The third-quarter (Q3) 2026 report, expected around 4 November 2026, settles whether clonoSEQ volume and the $268–278 million FY2026 minimal residual disease (MRD) revenue guidance support the re-rating.
The shares closed at $26.09 on 8 October 2026 in adjusted daily closes, 12.6% below the $29.84 52-week closing high of 5 October 2026 and still up 24.1% over three months. The slide continued after the 9.8% drop to $26.90 on 6 October 2026, which GuruFocus and Quiver Quantitative tied to profit-taking with no new company-specific setback. No company release or new SEC filing has appeared since.
The narrative is maturing: the National Comprehensive Cancer Network (NCCN) update on 17 September 2026, the International Myeloma Society (IMS) cure definition on 25 September 2026 and three analyst target moves by 1 October 2026 are well known, and no new rating action has surfaced since then while the shares fell three of the last four sessions through 8 October 2026. The view fails on a weekly close below $25, or if the Q3 report cuts MRD revenue guidance.
Bullish and bearish views on Adaptive Biotechnologies Corporation
The bull case on Adaptive Biotechnologies Corporation (ADPT), in brief: Guidelines add repeat testing occasions. The bear case: Company-wide profit is still a goal.
Bull case
- Guidelines add repeat testing occasions. Adaptive's 17 September 2026 release says the NCCN update names clonoSEQ for MRD assessment in multiple myeloma, including annual testing during maintenance therapy. Each annual test is a repeat order for a patient already being monitored.
- The cure definition requires multiple tests. The IMS definition highlighted by Adaptive on 25 September 2026 needs at least four negative MRD results over five years at a sensitivity of one cancer cell in a million, the level clonoSEQ is built to reach.
- Demand already has scale. The 29 July 2026 Q2 release reported 36,111 clonoSEQ tests, up 43% year over year (YoY), and MRD revenue of $66.2 million, up 33% and 92% of total revenue. Management raised FY2026 MRD revenue guidance to $268–278 million from $260–270 million, which the company said implies 26–31% growth.
- Analyst targets sit above the price. Goldman Sachs initiated at Buy with a $35 target on 29 September 2026, BTIG raised to $34 from $25 on 22 September 2026, and Guggenheim raised to $32 from $25 on 1 October 2026, per Benzinga. MarketBeat's consensus target was $28.94 on 5 October 2026, above the $26.09 close on 8 October 2026.
- The profit gap is small. Q2 2026 adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) was -$0.7 million, against -$7.2 million a year earlier.
Bear case
- Company-wide profit is still a goal. The Q2 2026 net loss was $39.9 million, including a $23.7 million loss on the OrbiMed settlement, per the 29 July 2026 8-K. Positive adjusted EBITDA and free cash flow are targeted only for the end of 2026.
- Insiders keep selling into strength. Quiver Quantitative counted 60 insider sales and no purchases in the six months to 1 October 2026, including about $16.6 million by Chief Executive Officer Chad Robins and about $21.3 million by Chief Scientific Officer Harlan Robins.
- The rally is unwinding. The shares fell 5.3% to $27.37 on 1 October 2026 and 9.8% to $26.90 on 6 October 2026, per GuruFocus, then closed at $26.09 on 8 October 2026. The 14-day relative strength index (RSI) stood at 39.5 on 8 October 2026, down from overbought readings during the September run.
- One product carries the valuation. Immune Medicine revenue fell 40% YoY to $5.4 million in Q2 2026, per the 8-K, and the planned separation of that unit has no announced structure or terms.
Price setup
The $26.09 close on 8 October 2026 sits 12.6% below the $29.84 52-week closing high from 5 October 2026. MarketBeat put the 50-day moving average at $25.78 on 5 October 2026, so the shares now trade only a short distance above it. The gap above the rising average that marked the September rally has largely closed.
The $25 level sits just under that 50-day average. A weekly close below it would put the shares under the average that tracked the summer and September advance. RSI at 39.5 shows selling pressure without a washed-out reading.
Crowding signals are mixed. Insider selling under Rule 10b5-1 plans (pre-arranged trading plans) continued into the 5 October 2026 high. The $345 million of zero-coupon convertible notes due 2031 can bring hedging-related short selling. The Q3 report, about four weeks out, is the next scheduled event.
Catalysts, next 30 days
- ~4 November 2026, est. Q3 2026 results. The company has not announced the date; third-party calendars list 4 November 2026 or 9 November 2026, after the close. This is the first clonoSEQ volume print since the NCCN and IMS updates and tests whether the $268–278 million MRD guidance and the end-2026 profit goal hold.
- 31 December 2026 — Immune Medicine separation path. Management's only dated commitment is to name a preferred path by year-end 2026.
- 31 December 2026 — Company-wide self-funding target. Management targets positive adjusted EBITDA and free cash flow by the end of 2026; Q2 adjusted EBITDA was -$0.7 million.
What would change the view
The case breaks if the Q3 report shows clonoSEQ volume growth falling well below the 43% YoY rate reported for Q2, or if management cuts FY2026 MRD revenue guidance below $268 million. A delay to the end-2026 adjusted EBITDA and free-cash-flow goal would also weaken it, because that goal underpins the 2026 re-rating.
On price, a weekly close below $25 would put the shares under the 50-day moving average and show the September gain unwinding before the report. The case would strengthen if Q3 volume growth holds near or above the Q2 rate and guidance rises again.
What it trades with
Adaptive trades as a small-to-mid-cap diagnostics name whose moves have been driven by company-specific news in 2026: the September rally followed the NCCN and IMS updates and analyst initiations. In the view taken here, it is likely to move with other MRD and oncology-diagnostics shares and with small-cap biotech sentiment on broad risk-off days. Convertible-note hedging can add selling pressure unrelated to the business.
Notes
- MRD testing was 92% of Q2 2026 revenue; Immune Medicine revenue fell 40% YoY to $5.4M as the research-use pharma services business winds down.
- Pharma milestone revenue is lumpy; a $9.0M milestone landed in Q1 2026, so underlying clonoSEQ growth is best judged excluding milestones.
- Not profitable under standard accounting (GAAP): the Q2 2026 net loss was $39.9M, including a $23.7M loss on the OrbiMed settlement.
- $345M of zero-coupon convertible notes due 2031 are outstanding; hedging by noteholders can add short selling in the shares.
- Several officers sell under standing Rule 10b5-1 plans, so planned insider sales recur regardless of price.
- The Immune Medicine separation is an intention with no structure or terms; a preferred path by year-end 2026 is the only dated commitment.
Related · shared themes
AZTA
Azenta, Inc.
Azenta's recovery case rests on its 9% June-quarter organic growth repeating and on an $11 million cost-cut plan announced in October; the fiscal fourth-quarter report, expected around 20 November 2026, shows whether revenue and free cash flow confirm it.
CAI
Caris Life Sciences, Inc.
Caris Life Sciences is growing revenue faster than its 27–28% FY2026 guidance implies, though a steep fourth-quarter 2025 comparison narrows the room for a raise; the third-quarter report expected around 4 November 2026 shows whether guidance rises above $1.040 billion.
CDNA
CareDx, Inc.
CareDx's shares have more than doubled in three months on a raised 2026 revenue guide and a higher preliminary Medicare rate for AlloSure; the third-quarter report, expected around 3 November 2026, tests whether revenue stays on track for the $490–500 million guide.
CSTL
Castle Biosciences, Inc.
Castle Biosciences' recovery rests on its TissueCypher Barrett's esophagus test growing volume 50–52% inside a $365–375 million 2026 revenue range. The third-quarter report, expected around 2 November 2026, tests both with the shares 21.7% below their 52-week high.
See also · stocks to watch